Document Detail


Immunotoxic effects of cyclophosphamide and cyclosporine in the dog.
MedLine Citation:
PMID:  23030398     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Limited non-clinical immunotoxicity data are available in the dog, although this is a major non-rodent species in regulatory safety studies. The present study aimed to test whether widely accepted immunotoxicity endpoints including lymphocyte subset immunophenotyping, the anti-KLH TDAR assay, and histological examination of the main lymphoid organs were reliable to detect immunosuppression induced by cyclosporine and cyclophosphamide in dogs and could, therefore, be used for non-clinical immunotoxicity evaluation in this species. Male and female Beagle dogs were treated orally from Day 1 for 4 weeks with 25 mg/kg cyclosporine daily, or with 2 mg/kg cyclophosphamide on 4 consecutive days each week, or the same volume of drinking water daily. Blood samples were withdrawn pre-test and on Days 11, 18, and 23 to measure standard hematology parameters and analyze lymphocyte subsets. All animals received an intramuscular injection of 5 mg KLH on Day 11. Sandwich ELISA assays were used to quantify anti-KLH IgM and anti-KLH IgG levels in blood samples taken pre-test, on Days 18 and 23, and pre-test, on Days 23 and 28, respectively. At the end of the treatment period, all animals were submitted to histological examination of lymphoid organs, liver, and kidneys. No signs of marked toxicity were observed. No changes in lymphocyte subsets, but markedly decreased primary anti-KLH IgM and IgG responses, and a slightly-to-markedly increased cortex/medulla ratio in the thymus were observed in cyclosporine-treated dogs. Lower total WBC counts correlating with lower total and B-lymphocyte subset and decreased germinal center development in mesenteric lymph nodes, but no changes in primary anti-KLH IgM and IgG responses were observed in cyclophosphamide-treated dogs. These results demonstrate that widely accepted immunotoxicity endpoints can adequately detect the effects of known immunosuppressive drugs in the dog and support the conclusion that it is a relevant animal species for immunotoxicity evaluation.
Authors:
Jean-Jacques Legrand; Caroline Bouchez; Cécile Mimouni; Armelle N'Guyen; Johanne Bouchard; Thibault Ameller; Jacques Descotes
Related Documents :
21145848 - Treatment of chronic hepatitis c patients with the ns3/4a protease inhibitor danoprevir...
15097958 - Low-dose uva1 phototherapy in systemic sclerosis: effects on acrosclerosis.
17089708 - Relating daily solar ultraviolet radiation dose in salt marsh-associated estuarine syst...
15309918 - Quantification of in vivo photofrin uptake by human pituitary adenoma tissue.
8257128 - Cgp 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 prot...
6202678 - Disulfiram implantation: a dose response trial.
Publication Detail:
Type:  Journal Article     Date:  2012-10-03
Journal Detail:
Title:  Journal of immunotoxicology     Volume:  10     ISSN:  1547-6901     ISO Abbreviation:  J Immunotoxicol     Publication Date:    2013 Jan-Mar
Date Detail:
Created Date:  2013-02-22     Completed Date:  2013-09-04     Revised Date:  2013-11-14    
Medline Journal Info:
Nlm Unique ID:  101201960     Medline TA:  J Immunotoxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  90-5     Citation Subset:  IM    
Affiliation:
CiToxLAB France, Evreux, France. jean-jacques.legrand@fr.citoxlab.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Biomarkers, Pharmacological / blood
Cyclophosphamide / administration & dosage,  adverse effects*
Cyclosporine / administration & dosage,  adverse effects*
Dogs / immunology*
Enzyme-Linked Immunosorbent Assay
Female
Hemocyanin / immunology
Immunoglobulin G / blood
Immunoglobulin M / blood
Immunosuppression*
Immunosuppressive Agents / administration & dosage,  adverse effects*
Lymphoid Tissue / drug effects*,  pathology
Male
Chemical
Reg. No./Substance:
0/Biomarkers, Pharmacological; 0/Immunoglobulin G; 0/Immunoglobulin M; 0/Immunosuppressive Agents; 50-18-0/Cyclophosphamide; 59865-13-3/Cyclosporine; 9013-72-3/Hemocyanin; FV4Y0JO2CX/keyhole-limpet hemocyanin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis of (R)-(+)-4-Methylcyclohex-2-ene-1-one.
Next Document:  Synthesis of Palladium Nanoparticles Supported on Mesoporous N-doped Carbon and Their Catalytic Abil...